TrialSeminars in arthritis and rheumatism2018

A randomized, double-blind, placebo-controlled trial of infliximab in refractory polymyositis and dermatomyositis.

Adam Schiffenbauer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.